Vicore Pharma Holding AB grossed about SEK500 million (US$46 million) in a directed share issue that will fund a phase IIb trial of its lead drug candidate, C-21, in idiopathic pulmonary fibrosis (IPF).
Lynk Pharmaceuticals Co. Ltd. raised ¥200 million (US$28 million) in a series C1 financing round to accelerate the clinical development of its second-generation and third-generation JAK inhibitors for cancer and autoimmune diseases.
Less than two years ago, in October 2021, a group of investors bid at auction on a promising monoclonal antibody to treat asthma, chronic rhinosinusitis and other inflammatory conditions, winning the asset known as UPB-101, the sole focus of the then-newly launched Upstream Bio Inc.
Gene therapy developer Kate Therapeutics Inc. (KateTx), which is developing next-generation adeno-associated virus (AAV) vectors that target skeletal and cardiac muscle, has unveiled $51 million series A round and a licensing deal with Astellas Pharma Inc.
Cellusion Inc. raised ¥2.83 billion (US$21 million) in a series C round to progress its lead therapy, CLS-001, an iPS cell-derived therapy to treat bullous keratopathy.
AAVantgarde Bio SrL raised €61 million (US$65 million) in series A funding to take forward two novel approaches to gene therapy that aim to overcome the packaging limits of adeno-associated virus (AAV) vectors. The company plans to move its lead program, in retinitis pigmentosa associated with Usher syndrome type 1b, into the clinic later this year. A second program, in Stargardt disease, is a couple of years behind it.
RSS
